Business Wire

DE-DERMALIQ

14.12.2022 14:27:37 CET | Business Wire | Press release

Share
Dermaliq Therapeutics Announces First Participant Randomized in Phase 1b/2 Trial Evaluating DLQ01 Solution for Treatment of Androgenic Alopecia

Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first participant randomized in a Phase 1b/2a trial with DLQ01 solution, a topical Prostaglandin F2α analogue. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ01 in men with androgenic alopecia (male pattern baldness).

“Topical application of prostaglandin F2α analogue eyedrops has already been demonstrated to grow eyelashes when used to treat glaucoma. These agents could potentially also stimulate hair regrowth in androgenic alopecia in man and woman. However, to date difficulties in topical delivery of this class of compounds into the hair follicle have limited their development,” said Prof. Rod Sinclair, MD, Professor of Dermatology at the University of Melbourne, and Director of Epworth Dermatology.

DLQ01 is designed to overcome the challenges of topical delivery of this drug class with an excellent safety profile. “This trial evaluates how the unique properties of a topical formulation based on hyliQ®, Dermaliq’s novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability, can facilitate targeted delivery of a Prostaglandin F2α analogue into hair follicles,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “We are convinced that Dermaliq’s hyliQ® technology has the potential to transform follicular and dermal delivery of a broad range of active ingredients and that DLQ01 is just the start of a promising pipeline targeting follicular delivery.”

This randomized, blinded, vehicle-controlled Phase 1b/2a trial at Sinclair Dermatology, Melbourne Australia is designed to evaluate the safety and efficacy profile over a 6-month treatment period of two dose strengths of DLQ01 and its vehicle and compared against the market product Rogaine® (Minoxidil) in men diagnosed with androgenic alopecia. A targeted total of 120 patients, 30 per treatment group, will be enrolled. Trial completion is expected in Q4 2023.

“DLQ01 is the third clinical trial in dermatology we initiated in 2022,” said Frank Loescher, PhD, CEO & President of Dermaliq. “This is a significant achievement towards Dermaliq's goal of developing a new drug category of superior topical prescription therapeutics alongside medical skin care OTC products that address the significant unmet medical need for safe and effective therapies for patients in dermatology.

Delivering clinical proof of concept data with our game-changing, proprietary, hyliQ® technology platform in three different major dermatology indications by 2023 will open the door to new partnerships and support our goal to become a leading, dermatology-focused pharmaceutical company with global reach.”

About DLQ01

DLQ01 solution is a topical prostaglandin (PG) F2α drug, designed to stimulate scalp hair growth in men and women suffering from androgenic alopecia, also known as male and female pattern baldness. DLQ01 has the potential to provide a highly effective and safe treatment option.

About Dermaliq:

Dermaliq Therapeutics, Inc. is a clinical stage pharmaceutical Delaware corporation founded in 2021 through a spin off from Novaliq GmbH to reimagine topical dermatology.

Dermaliq’s mission is to develop a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The unique “hyliQ®” technology is driving a growing product pipeline in key dermatological indications. We expect that the hyliQ® technology will offer superior bioavailability, stability and cosmetic acceptability as compared to currently marketed products.

Earlier this year, Dermaliq secured USD 15 million in a series A round to advance the development of three transformative skin care drug therapies including DLQ01. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd.

Forward-Looking Disclosures:

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. The information contained in this release is as of December 15, 2022. Dermaliq assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a potential topical treatment for androgenetic alopecia, DLQ01, including its potential benefits and a Phase 1b/2a clinical trial that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. You should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety, and efficacy of DLQ01, hyliQ®, or any of Dermaliq’s other product candidates, the potential benefits or applications of Dermaliq’s hyliQ® technology, Dermaliq’s ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of DLQ01 and other product candidates, and the timing the commencement of clinical trials, initial and ongoing data availability, and other development milestones.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005635/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Klarna Reports Third Quarter 2026 Results17.11.2026 13:45:00 CET | Press release

Klarna Group plc (NYSE: KLAR), the everyday finance network, today reported third quarter 2026 results. GMV reached $36.1 billion (+10% YoY), revenue $1.0 billion (+12% YoY), transaction margin dollars (TMD) $371 million (+32% YoY), and adjusted operating income $21 million (+$35m YoY). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116206092/en/ "Q3 was our fourth straight quarter with revenue above 1 billion dollars and positive adjusted operating income. We are keeping more of each dollar we process through our everyday finance network: transaction margin is now 37% of revenue, up from 31% a year ago. Looking ahead, we’re finishing the year strong as we are running on track with, or ahead of, all our full year outlook.” Sebastian Siemiatkowski, CEO & Co-Founder, Klarna Klarna’s full earnings release is available at the Quarterly Results section of its website at https://investors.klarna.com/financials/quarterly-results

Would You Let AI Manage Your Next Trip?17.11.2026 13:06:00 CET | Press release

New research suggests AI agents could change how travelers choose airlines and hotels by 2032The Intelligent Journey 2032 explores four directions travel could take by early in the next decade, and how technology, particularly AI, will connect travelers with airlines, airports, hotels and other travel companies.The study suggests the future will be defined by travelers deciding what they are willing to delegate, with clear consent, spending limits, and the ability to retain control as key considerations.It also identifies travel orchestration as the strategic prize for the industry, as AI could reshape travel commerce, and shift value toward those able to coordinate the entire journey across suppliers, payments, identity, disruption and service. AI is already transforming the traveler journey, helping people discover, plan and navigate their trips. The question is how far travelers will let AI make decisions for them in the future: booking, paying, changing plans and recovering from di

Iconic Raises $10M to Build Software That Understands the World’s Biggest Projects17.11.2026 13:01:00 CET | Press release

Iconic has raised $10 million in seed funding led by Peak Capital, with participation from Bridford Group, Common Magic, Graduate Ventures, NP-Hard, and Tiny VC. Since its founding in mid-2025, Iconic has signed five clients in energy, infrastructure, and AI infrastructure: a global energy major, a leading European utility, a major European airport, a European rail infrastructure owner, and a global contractor building semiconductor fabs and data centers. Each spends over $1 billion annually on capital projects. An estimated $15 trillion is invested in capital projects annually, yet fewer than 3% are delivered on time, on budget, and to plan. Capital projects rarely fail because of engineering complexity, but because decisions are made without a complete understanding of the project. Information is fragmented across documents and systems shared by owners, contractors, and engineering firms. Decisions are hard to reverse, with consequences lasting years through delays, claims, and cost

Quaise Energy Signs 50 MW Geothermal Power Purchase Agreement with Google17.11.2026 12:50:00 CET | Press release

Agreement advances development of commercial-scale superhot geothermal, will supply carbon-free energy to Oregon communities as early as 2030 Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that Google has signed a power purchase agreement (PPA) for 50 megawatts (MW) of superhot geothermal power from Project Obsidian, Quaise’s flagship project in Central Oregon. Once online, this always-on, carbon-free energy is slated to support Google’s existing data center operations in The Dalles, Ore. and the region’s communities. The agreement will help catalyze the commercial development of superhot geothermal energy, providing benefits for ratepayers and helping protect the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117923219/en/ Beginning as early as 2030, Google will purchase 50 MW of power from Project Obsidian. The initial phase of development will use convention

Nowhere to Sit, Nothing to Do: Europe’s Biggest Airports Fall Short for Passengers17.11.2026 12:24:00 CET | Press release

AirHelp data shows that nearly half of Europe’s biggest airports score below the global average for both seating and entertainment. One in four of Europe’s 50 biggest airports scores below the global average on all four parts of the experience passengers rated, according to AirHelp data covering 279 airports worldwide. Passengers rated each airport on wait times, restaurants, seating and entertainment. Twelve airports, including Dublin, Manchester, Lisbon, London Luton and Milan Bergamo, came in below the global average on all four. Only four beat all four averages: Zurich, Warsaw, Naples and Ankara. Entertainment is the weak spot almost everywhere Entertainment was the lowest-rated part of the experience at 45 of the 50 airports, averaging 6.5 out of 10, with more than half of the airports falling below the global average of 6.7. Seven airports scored less than 6, including Manchester, Stansted, Dublin and Oslo. The data also suggests that passengers who can’t find a seat usually have

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye